Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933368 | 0.87 | CYP4A11 (0.59) | PLA2G10PLA2G2APARP10CYP4A11CYP4F2 | |
| SCHEMBL9761155 | 0.85 | CYP4A11 (0.61) | PLA2G10PLA2G2APARP10CYP4A11CYP4F2 | |
| Hydrochloric Acid SCHEMBL10622023 | 0.85 | CYP4A11 (0.58) | PLA2G10PLA2G2APARP10CYP4A11CYP4F2 | |
| Terephthalamide SCHEMBL27383156 | 0.83 | PARP1 (0.57) | PLA2G10PLA2G2APARP10CA2CA12 | |
| SCHEMBL8867699 | 0.82 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CA2CA1 | |
| SCHEMBL2861358 | 0.82 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CA2CA12 | |
| SCHEMBL873232 | 0.81 | PRSS1 (0.60) | PLA2G10PLA2G2APARP10CA2CA12 | |
| SCHEMBL4073172 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2APARP10CA2CA1 | |
| SCHEMBL5536952 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2APARP10CA2CA1 | |
| SCHEMBL5648580 | 0.80 | PLA2G10 (0.53) | PLA2G10PLA2G2APARP10CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| EP-1453831-A1 | 1H-PYRROLO(3,2-B)PYRIDINE-3-CARBOXYLIC ACID AMIDES | Neurogen Corporation (US) | 2004-09-08 | — | — | EP | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| WO-2003044018-A1 | 1H-PYRROLO[3,2-B]PYRIDINE-3-CARBOXYLIC ACID AMIDES | NEUROGEN CORPORATION (US) | 2003-05-30 | — | — | WO | claimed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| CN-107531641-A | Oxazoline ring-containing compound, material for electron transport/injection layer containing the same, and organic electroluminescent element using the same | 捷恩智株式会社 | 2018-01-02 | — | — | CN | disclosed |
| EP-2465850-B1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2016-11-23 | — | — | EP | disclosed |
| US-6030984-A | 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5869500-A | INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998025930-A2 | USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-18 | — | — | WO | disclosed |
| US-5686484-A | ANTHELMINTICS, ACARICIDES, INSECTICIDES | SANKYO CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | PLA2G10 3851/4885PLA2G2A 2178/4885PARP10 1840/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | PLA2G10 3539/4885PLA2G2A 3896/4885PARP10 836/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PLA2G10 3250/4885PLA2G2A 4055/4885PARP10 1586/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | PLA2G10 141/4885PLA2G2A 194/4885PARP10 3086/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | PLA2G10 2885/4885PLA2G2A 1333/4885PARP10 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.